Literature DB >> 34532112

Expression, clinical significance and correlation of RUNX3 and HER2 in colorectal cancer.

Yunshi Wu1, Jun Xue2, Yuanrui Li3, Xueliang Wu2, Ming Qu2, Dandan Xu4, Yongquan Shi4.   

Abstract

BACKGROUND: The incidence of colorectal cancer is high and on the rise. The genetic and protein expressions of RUNT-associated transcription factor 3 (RUNX3) and human epidermal growth factor receptor 2 (HER2) in colorectal cancer (CRC) and adjacent normal tissues were detected to preliminarily explore their correlation and clinical significance.
METHODS: CRC specimens excised during general surgery were selected for localization and quantitative analysis of protein and gene expression by SP (Streptavidin-peroxidase conjugated method) immunohistochemical staining, reverse transcription-polymerase chain reaction (RT-qPCR) and western blot. Combined with the patients' data, the relationship between the expression of the two genes and tumor characteristics was analyzed. Log-rank test was used to analyze the correlation between the two proteins and survival prognosis of CRC patients. The expression of RUNX3 in RKO and HCT-116 was knocked down, and the relative expression of HER2 in the two cell lines was detected.
RESULTS: Immunohistochemical, RT-qPCR and Western blot results showed that the positive expression rate of RUNX3 in CRC was lower than in the normal group, and HER2 in CRC was higher than in the normal group. The positive expression of the two proteins correlated with the pT and pN stages of CRC. A significant negative correlation between the expression of the two genes in CRC. Follow-up results showed that the number of Runx3-positive patients was higher than negative ones, while HER2 positive were fewer than negative ones. In vitro experiments showed that RUNX3 protein and gene expression decreased, HER2 protein and gene expression increased in RUNX3 knockdown RKO and HCT-116 cells, respectively (P<0.05).
CONCLUSIONS: The expression of RUNX3 and HER2 in CRC is related to the occurrence and development of CRC, and the two genes have a negative regulating effect. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Colorectal cancer (CRC); HER2; RUNX3; molecular markers

Year:  2021        PMID: 34532112      PMCID: PMC8421900          DOI: 10.21037/jgo-21-403

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  18 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer.

Authors:  Giulia Siravegna; Andrea Sartore-Bianchi; Rebecca J Nagy; Kanwal Raghav; Justin I Odegaard; Richard B Lanman; Livio Trusolino; Silvia Marsoni; Salvatore Siena; Alberto Bardelli
Journal:  Clin Cancer Res       Date:  2019-02-26       Impact factor: 12.531

3.  Inactivation of RUNX3 predicts poor prognosis in esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.

Authors:  Mo Shi; Zhou Wang; Xiang-Yan Liu; Dong Chen
Journal:  Med Oncol       Date:  2014-11-13       Impact factor: 3.064

4.  [Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2020 edition)].

Authors: 
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2020-08-01

5.  Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.

Authors:  Lei Zhang; Xin Yu; Liangtao Zheng; Yuanyuan Zhang; Yansen Li; Qiao Fang; Ranran Gao; Boxi Kang; Qiming Zhang; Julie Y Huang; Hiroyasu Konno; Xinyi Guo; Yingjiang Ye; Songyuan Gao; Shan Wang; Xueda Hu; Xianwen Ren; Zhanlong Shen; Wenjun Ouyang; Zemin Zhang
Journal:  Nature       Date:  2018-10-29       Impact factor: 49.962

6.  Correlation of RUNX3 expression with microvessel density in colorectal adenocarcinoma tissues and clinical significance.

Authors:  Jun Xue; Xue-Liang Wu; Xian-Tao Huang; Ming Qu; Fei Guo; Guang-Yuan Sun; Peng-Cheng Zhang; Lei Han; Li-Ming Pan
Journal:  Asian Pac J Trop Med       Date:  2016-12-27       Impact factor: 1.226

7.  Runx3 transcription factor regulates ovarian functions and ovulation in female mice.

Authors:  Fumiya Ojima; Yuka Saito; Yukiko Tsuchiya; Daichi Kayo; Syusuke Taniuchi; Maho Ogoshi; Hiroshi Fukamachi; Sakae Takeuchi; Sumio Takahashi
Journal:  J Reprod Dev       Date:  2016-06-13       Impact factor: 2.214

Review 8.  An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.

Authors:  De-Guo Lu; Ying-Mei Ma; Ai-Ju Zhu; Yun-Wei Han
Journal:  Oncotarget       Date:  2017-03-28

9.  USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination.

Authors:  Laura Novellasdemunt; Valentina Foglizzo; Laura Cuadrado; Pedro Antas; Anna Kucharska; Vesela Encheva; Ambrosius P Snijders; Vivian S W Li
Journal:  Cell Rep       Date:  2017-10-17       Impact factor: 9.423

10.  Methylation analysis of p16, SLIT2, SCARA5, and Runx3 genes in hepatocellular carcinoma.

Authors:  Gaofeng Sun; Chen Zhang; Min Feng; Wensheng Liu; Huifang Xie; Qin Qin; E Zhao; Li Wan
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.817

View more
  1 in total

1.  Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer.

Authors:  Likun Wang; Xueliang Wu; Wengui Xu; Lei Gao; Ximo Wang; Tian Li
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.